Everything below concerns albumin conjugate. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
== Properties == Actinides have similar properties to lanthanides. Just as the 4f electron shells are filled in the lanthanides, the 5f electron shells are filled in the actinides. Because the 5f, 6d, 7s, and 7p shells are close in energy, many irregular configurations arise; thus, in gas-phase atoms, just as the first 4f electron only appears in cerium, so the first 5f electron appears even later, in protactinium. However, just as lanthanum is the first element to use the 4f shell in compounds, so actinium is the first element to use the 5f shell in compounds. The f-shells complete their filling together, at ytterbium and nobelium. The first experimental evidence for the filling of the 5f shell in actinides was obtained by McMillan and Abelson in 1940. As in lanthanides (see lanthanide contraction), the ionic radius of actinides monotonically decreases with atomic number (see also actinoid contraction). The shift of electron configurations in the gas phase does not always match the chemical behaviour. For example, the early-transition-metal-like prominence of the highest oxidation state, corresponding to removal of all valence electrons, extends up to uranium even though the 5f shells begin filling before that. On the other hand, electron configurations resembling the lanthanide congeners already begin at plutonium, even though lanthanide-like behaviour does not become dominant until the second half of the series begins at curium.
=== Legal status === Empagliflozin/metformin was approved for use in the European Union in May 2015. Empagliflozin/metformin was approved for use in the United States in August 2015. The extended release version was approved for use in the United States in December 2016. Empagliflozin/metformin was approved for use in Australia in May 2020.
Odd-chain fatty acids can be oxidized to yield acetyl-CoA and propionyl-CoA, the latter serving as a precursor to succinyl-CoA, which can be converted to oxaloacetate and enter into gluconeogenesis. In contrast, even-chain fatty acids are oxidized to yield only acetyl-CoA, whose entry into gluconeogenesis requires the presence of a glyoxylate cycle (also known as glyoxylate shunt) to produce four-carbon dicarboxylic acid precursors. The glyoxylate shunt comprises two enzymes, malate synthase and isocitrate lyase, and is present in fungi, plants, and bacteria. Despite some reports of glyoxylate shunt enzymatic activities detected in animal tissues, genes encoding both enzymatic functions have only been found in nematodes, in which they exist as a single bi-functional enzyme. Genes coding for malate synthase alone (but not isocitrate lyase) have been identified in other animals including arthropods, echinoderms, and even some vertebrates. Mammals found to possess the malate synthase gene include monotremes (platypus) and marsupials (opossum), but not placental mammals. The existence of the glyoxylate cycle in humans has not been established, and it is widely held that fatty acids cannot be converted to glucose in humans directly. Carbon-14 has been shown to end up in glucose when it is supplied in fatty acids, but this can be expected from the incorporation of labelled atoms derived from acetyl-CoA into citric acid cycle intermediates which are interchangeable with those derived from other physiological sources, such as glucogenic amino acids.
Samples of water from the natural environment are routinely taken and analyzed as part of a pre-determined monitoring program by regulatory authorities to ensure that waters remain unpolluted, or if polluted, that the levels of pollution are not increasing or are falling in line with an agreed remediation plan. An example of such a scheme is the harmonized monitoring scheme operated on all the major river systems in the UK. The parameters analyzed will be highly dependent on nature of the local environment and/or the polluting sources in the area. In many cases the parameters will reflect the national and local water quality standards determined by law or other regulations. Typical parameters for ensuring that unpolluted surface waters remain within acceptable chemical standards include pH, major cations and anions including ammonia, nitrate, nitrite, phosphate, conductivity, phenol, chemical oxygen demand (COD) and biochemical oxygen demand (BOD).
== Cultural response == Though intended as a parody, the single popularized the valley girl stereotype nationwide. Following the single's release, there was a significant increase in "valleyspeak" slang usage, whether ironically spoken or not. In particular, the film Valley Girl (1983) capitalized on this cultural curiosity. Zappa expressed concern that, despite his rich body of music, he was seen as a "novelty" artist because of songs like "Valley Girl" and "Don't Eat the Yellow Snow". At the time of the single's release, Moon said, "I am not a valley girl, but I guess that is my claim to fame." Mimi Pond created a comic book about the song, The Valley Girl's Guide to Life, which launched her career. A parody entitled "Valley Dudes" was recorded in 1982 by The Straight A's. On September 16, 2022 (3 months after the single's 40th anniversary), Universal Music Group (who acquired the Zappa catalogue in June of the same year) released an animated music video for the song.
Sources: en.wikipedia.org
A dose-sparing syringe is one which minimises the amount of liquid remaining in the barrel after the plunger has been depressed. These syringes feature a combined needle and syringe, and a protrusion on the face of the plunger to expel liquid from the needle hub. Such syringes were particularly popular during the COVID-19 pandemic as vaccines were in short supply.
=== Surgery === Bariatric surgery is a common cause of copper deficiency. Bariatric surgery, such as gastric bypass surgery, is often used for weight control of the morbidly obese. The disruption of the intestines and stomach from the surgery can cause absorption difficulties not only as regards copper but also for iron and vitamin B12 and many other nutrients. The symptoms of copper deficiency myelopathy may take up to decades to develop.
=== PDF generation === ColdFusion can generate PDF documents using standard HTML (i.e. no additional coding is needed to generate documents for print). CFML authors place HTML and CSS within a pair of cfdocument tags (or new in ColdFusion 11, cfhtmltopdf tags). The generated document can then either be saved to disk or sent to the client's browser. ColdFusion 8 introduced also the cfpdf tag to allow for control over PDF documents including PDF forms, and merging of PDFs. These tags however do not use Adobe's PDF engine but cfdocument uses a combination of the commercial JPedal Java PDF library and the free and open source Java library iText. The library used by cfhtmltopdf since cf11 has been an embedded WebKit IMPLEMENTATION. Since cf2023, Adobe has licensed PDFReactor to be the default engine underlying cfhtmltopdf.
== Further reading == Naughton, Frank. "Castor Oil". Kirk-Othmer Encyclopedia of Chemical Technology. New York: John Wiley. doi:10.1002/0471238961.0301192014012107.a01.pub2. ISBN 9780471238966 – overview of chemical properties and manufacturing of castor oil
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.